ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates

March 26, 2004

Hearing Probes CDC On Cancer Treatment For Working Poor In Screening Program

July 23, 1999

Drugs Available To Investigators Centers to Monitor Them Are Listed

September 9, 1977

Stop Cancer Foundation’s Future In Question, May Not Deliver All Of Funds Promised to NCI

January 18, 1991

Authorization Legislation Still On Congress Busy Agenda, Along With Risk Assessment, Appropriations

February 3, 1984

July issue of Business & Regulatory report (8 additional pages) included.

July 30, 2004